Mean Platelet Volume in Heterozygous Beta Thalassaemia

Çıkrıkçıoğlu, Mehmet Ali; Çelik, Kenan; Ekinci, İskender; Nasifov, Muharrem; Toprak, Aybala Erek; Çetin, Güven; Genç, Sema Yılmaz

doi:10.1159/000455813

Cited by 7 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, MPV denotes the status of thrombopoiesis in the bone marrow, and higher MPV values are associated with increased bone marrow activity [27]. Mean platelet value was also increased in patients with heterozygous beta thalassemia, who had mild ineffective hematopoiesis and hemolysis [28]. Similar to the previous studies, MPV was increased in patients with the diagnosis of ET compared to the patients with reactive thrombocytosis [11] and healthy individuals [10,11].…”

Section: Discussionsupporting

confidence: 75%

The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study

Eren¹,

Doğu²,

Koç³

et al. 2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: Essential thrombocythemia (ET) patients exhibit higher mean platelet volume (MPV) values compared to the healthy individuals. However, the association of degree of bone marrow fibrosis with either MPV or platecrit (PCT) has not been evaluated previously. The aim of this study was to investigate MPV and PCT values as predictive markers for evaluating bone marrow fibrosis (BMF) in ET patients. Methods: We conducted a retrospective cohort study to analyze the data of ET patients, who were followed in outpatient clinic of our hematology department, between January 2015 and December 2016. Patients older than 18 years, who had bone marrow biopsy, CBC, biochemistry tests and an abdominal sonography performed at the time of diagnosis, JAK2 test ordered and were BCR-ABL negative were included in the study. The patients were divided into two groups according to the presence of BMF as "the BMF group" and "the non-BMF group". The cutoff value for MPV and PCT was determined according to the median value. Fisher's exact test and χ 2 were used for comparative statistical analysis. Results: There were 22 males and 26 females with a median age of 56 years (range, 28-81). The BMF group included 35 (73%) patients while the non-BMF group included 13 (27%) patients. The median MPV was 8.8 fL (6.6-11.5) and median PCT was 0.69% (0.42-2.26), which was considered as the cutoff values for these parameters. There was no significant difference between the groups in patients with MPV ≤8.8 fL and MPV >8.8 fL (p=0.104) and also in patients with PCT ≤0.69% and PCT >0.69% (p=0.616). Conclusion: There is no association between the BMF and MPV and PCT in ET patients. However this is the first study investigating the role of both MPV and PCT in BMF in ET patients.

show abstract

Section: Discussionsupporting

confidence: 75%

The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study

Eren¹,

Doğu²,

Koç³

et al. 2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

show abstract

“…Elevated MPV is another indicator of platelet activation, leading to thrombosis [25,26]. Çıkrıkçıoğlu et al [27] found higher MPV values in β Thalassemia intermedia. However, we have not detected any correlation between D-dimer and homocysteine levels.…”

Section: Discussionmentioning

confidence: 99%

Investigation of SCUBE-1 levels in pediatric patients with beta-thalassemia

Acıpayam¹,

Tuncel²,

Güneş³

et al. 2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: A thrombosis and inflammation marker, Signal peptide-CUB (complement C1r/C1 s)-EGF (epidermal growth factor)-like domaincontaining protein 1 (SCUBE-1) is expressed in endothelial cells and activated platelets. We aimed to investigate the levels of this marker in patients with Thalassemia major (TM), a disease which causes a tendency to thrombosis. Methods: Twenty patients with TM and age and gender-matched twenty healthy controls were included in this prospective case-control study. Other thrombosis markers such as D-dimer and homocysteine were studied in addition to SCUBE-1 in both groups. Results: The SCUBE1 and D-dimer levels were higher in the TM group compared to the control group (P=0.004, P=0.023, respectively). A significant positive correlation was detected between platelet count and SCUBE1 (r=0.342, P=0.031). Conclusion: We detected elevated SCUBE1 levels in children with TM compared to the healthy controls, which correlated with platelet count. SCUBE1 may be used as a thrombosis marker in TM in the early stages of the disease.

show abstract

“…In another study, Labib et al [11] found no significant difference as regard platelet counts but a significant higher MPV was found in BTC subjects compared with controls. On the other hand, Cikrikcioglu et al [12] found in the study that, the MPV levels were unexpectedly higher in patients in the BTC group than in the control group. In our study, the children with group 1 lower mean levels of MPV than those with group 2, however there were no statistical differences in MPV (p>0.05), moreover, there were inverse correlations between thrombocyte counts and MPV levels (r=0.18, p<0.05).…”

Section: Discussionmentioning

confidence: 81%

“…[7][8][9] Several studies reported an inverse relationship between mean platelet volume (MPV) and platelet counts in patients with BTC. [10][11][12] This may be related to morphological features of platelets. In the literature, there are also some informations about platelet indices in BTC.…”

Section: Introductionmentioning

confidence: 99%

Relationship between platelet counts, mean platelet volume, platecrit and Beta Thalassemia Carriers

Akbayram

Örkmez

2020

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Aim: β-thalassemia carriers (BTC) is generally asymptomatic; however, in clinical practice, there is hypochromic microcytic mild anemia caused by a hereditary reduction in beta globin synthesis. In the literature, there is also some information about platelet indices in BTC. The aim of this study was to evaluate platelet indices in children with BTC. In addition, we compared platelet indices between anemia (Hb<11 g/dl) and non-anemia BTC (Hb ≥11 g/dl). Material and Method: A cross sectional study included a total of 153 subjects aged 1-16 years were recruited from Gaziantep University Hospital outpatient clinics electronic database. Results: Platelet counts were normal in 90 patients with BTC. Thrombocytosis and thrombocytopenia were detected in 59 (38.5%) and four (2.6%) patients, respectively. This study group was divided into two groups as group 1, cases<11 g/dl (n=86), and group 2, cases≥11g/dl (n=67) according to the hemoglobin levels. The children with the group 1 had significantly higher mean levels of platelet counts and platecrit than those with group 2 (p<0.05). In the logistic regression test, linear correlation between platelet counts and platecrit (r=0.94, p<0.01) was observed, whereas there were inverse correlations between platelet counts and age (r=-0.32, p<0.01), mean platelet volume (r=-0.18, p<0.05), hemoglobin (r =-0.18, p<0.05). Conclusion: We found that both thrombocytosis and thrombocytopenia may occur in BTC. Herein we also found significantly elevated platelet counts in BTC with anemia.

show abstract

Mean Platelet Volume in Heterozygous Beta Thalassaemia

Cited by 7 publications

References 23 publications

The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study

The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study

Investigation of SCUBE-1 levels in pediatric patients with beta-thalassemia

Relationship between platelet counts, mean platelet volume, platecrit and Beta Thalassemia Carriers

Contact Info

Product

Resources

About